Gain Therapeutics (NASDAQ:GANX) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Gain Therapeutics (NASDAQ:GANX) released its earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.07, Zacks reports.

Gain Therapeutics Stock Down 8.7 %

Shares of GANX opened at $1.89 on Friday. The company has a market capitalization of $50.13 million, a price-to-earnings ratio of -1.72 and a beta of 0.14. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.04. The stock’s 50-day moving average price is $2.22 and its 200-day moving average price is $2.06. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on GANX shares. Scotiabank started coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price objective for the company. Roth Mkm reiterated a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Chardan Capital reaffirmed a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Monday, March 17th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Gain Therapeutics presently has an average rating of “Buy” and a consensus price target of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.